Metabolic Slowing and Reduced Oxidative Damage with Sustained Caloric Restriction Support the Rate of Living and Oxidative Damage Theories of Aging

Graphical Abstract

Highlights

- Calorie restriction (CR) extends maximum lifespan in most species
- Young, healthy individuals achieved 15% CR and 8 kg weight loss over 2 years
- Energy expenditure (24 hr and sleep) was reduced beyond weight loss
- Oxidative stress was also reduced, supporting two long-standing theories of aging

Authors
Leanne M. Redman, Steven R. Smith, Jeffrey H. Burton, Corby K. Martin, Dora Il'yasova, Eric Ravussin

Correspondence
leanne.redman@pbrc.edu

In Brief
Calorie restriction (CR) has been shown to have health benefits and to extend lifespan in diverse species. Redman et al. conducted a 2-year CR trial in healthy, non-obese humans and found evidence that prolonged CR enhances resting energy efficiency, resulting in decreased systemic oxidative damage.
Metabolic Slowing and Reduced Oxidative Damage with Sustained Caloric Restriction Support the Rate of Living and Oxidative Damage Theories of Aging

Leanne M. Redman,1,4,∗ Steven R. Smith,2 Jeffrey H. Burton,1 Corby K. Martin,1 Dora Il’yasova,3 and Eric Ravussin1
1Division of Clinical Sciences Pennington, Biomedical Research Center, 6400 Perkins Road, Baton Rouge, LA 70808, USA
2Translational Research Institute for Metabolism and Diabetes, Florida Hospital and Sanford-Burnham Medical Research Institute, Orlando, FL 32804, USA
3School of Public Health, Georgia State University, Atlanta, GA 30302, USA
4Lead Contact
∗Correspondence: leanne.redman@pbrc.edu
https://doi.org/10.1016/j.cmet.2018.02.019

SUMMARY

Calorie restriction (CR) is a dietary intervention with potential benefits for healthspan improvement and lifespan extension. In 53 (34 CR and 19 control) non-obese adults, we tested the hypothesis that energy expenditure (EE) and its endocrine mediators are reduced with a CR diet over 2 years. Approximately 15% CR was achieved over 2 years, resulting in an average 8.7 kg weight loss, whereas controls gained 1.8 kg. In the CR group, EE measured over 24 hr or during sleep was approximately 80–120 kcal/day lower than expected on the basis of weight loss, indicating sustained metabolic adaptation over 2 years. This metabolic adaptation was accompanied by significantly reduced thyroid axis activity and reactive oxygen species (F2-isoprostane) production. Findings from this 2-year CR trial in healthy, non-obese humans provide new evidence of persistent metabolic slowing accompanied by reduced oxidative stress, which supports the rate of living and oxidative damage theories of mammalian aging.

INTRODUCTION

For the past 40 years, aging research has focused on the mechanisms underlying the beneficial health impact of a sustained reduction in caloric intake below usual levels, while maintaining adequate intake of essential nutrients. Observations in a variety of laboratory animals indicate that calorie restriction (CR), beginning early or in mid-life and sustained for a substantial portion of the lifespan, increases longevity in a wide variety of, but not all, species (Speakman and Mitchell, 2011). While the field of CR research eagerly awaits final lifespan data from the two remaining colonies of CR primates (Colman et al., 2009; Mattison et al., 2012), despite differences in study designs, current data support the observation that sustained CR extends life without chronic disease and promotes a more youthful physical and mental functionality (Mattison et al., 2017). In terms of CR in humans, few controlled clinical trials exist, and much of what is known has been derived from observational and cross-sectional studies of individuals who are long-lived such as the centenarians who reside in Okinawa, Japan (Willcox et al., 2006), or individuals self-practicing CR who are members of the CR optimal nutrition society (Fontana et al., 2004).

A variety of mechanisms have been proposed as mediators of the effects of CR on lifespan. An old but arguably a prevailing theory supporting lifespan extension with CR is a hybrid between two long-standing hypotheses of aging: the “rate of living” and the “oxidative damage” theories of aging. Pearl (1928) proposed the idea that mammalian longevity is inversely related to their metabolic rate per unit of tissue mass; hence, rate of living. Several decades later, Harman (1956) proposed the oxidative damage theory of aging and suggested that reactive oxygen species (ROS)—byproducts of oxidative phosphorylation in mitochondria—damage DNA, lipids, and proteins, all leading to accelerated biological aging. There are data from studies in rodents (Hambly and Speakman, 2005), non-human primates (Blanc et al., 2003; Ramsey et al., 1997), and humans (Heilbronn et al., 2006) indicating that CR results in a decrease in metabolic rate that is greater than that expected on the basis of loss of tissue mass (Heilbronn et al., 2006; McCarter and Palmer, 1992). This phenomenon, referred to as metabolic adaptation, was associated with less oxidative damage to DNA in our 6-month pilot study of CR in humans (Heilbronn et al., 2006). The CR field has also focused on the ability for CR to attenuate age-related changes in physiological and endocrine factors that are known to change with age, such as core body temperature, plasma insulin, DHEAS, and thyroid hormones (Roth et al., 2002b), as well as endocrine mediators of metabolic slowing such as plasma leptin (Rosenbaum et al., 2005).

Phase 1 CALERIE or the Comprehensive Assessment of the Long-Term Effects of Reducing Intake of Energy studies were the first randomized controlled trials to test the metabolic effects of CR in non-obese humans (Das et al., 2009; Heilbronn et al., 2006; Weiss et al., 2006). Then, the phase 2 CALERIE study, a 2-year 25% CR prescription in non-obese volunteers, was shown to be safe and without any untoward effects on quality of life (Martin et al., 2016; Rickman et al., 2011; Rochon et al., 2011; Romashkan et al., 2016). Importantly, the study confirmed...
the presence of a CR-induced decrease in total daily energy expenditure (EE) measured by doubly labeled water after 12 and 24 months (measured CR was 12% on average), indicating a decrease in physical activity and/or a metabolic adaptation. However, in the CR group compared with the control group, resting metabolic rate adjusted for loss of fat-free and fat masses was only lower during the weight loss phase, i.e., at 12 months of intervention (Ravussin et al., 2015), but not a year later. Furthermore, reductions in core body temperature were noted in the CR group, but were not different from the controls, and changes in oxidative damage were not assessed.

As an ancillary study of the multi-center CALERIE phase 2 trial, individuals studied at Pennington Biomedical Research Center underwent additional procedures to assess changes in the different components of sedentary EE measured in a metabolic chamber (more precise measure of daily EE including sleeping metabolic rate) after 1 and 2 years of CR. Importantly, we also measured changes in potential metabolic mediators and biomarkers of aging mediators such as core temperature, thyroid hormones, leptin, and insulin, as well as downstream effectors including lipid peroxidation and DNA damage, markers of oxidative stress. We hypothesized that, after 1 year, EE would be lower than that expected on the basis of the loss in energetically active tissues (fat-free mass and fat mass) and that this metabolic adaptation will still be present after another year of sustained CR and weight stability, as previously shown in obese individuals (Rosenbaum et al., 2008). Furthermore, following from our 6-month pilot CR study, we hypothesized a reduction in oxidative damage after 1 and 2 years of CR. Taken together, such results would speak in favor of the long-standing hypotheses of biological aging stating that prolonged CR enhances energy efficiency at rest and therefore results in less ROS production and reduced oxidative damage to tissues and organs, thus a combination of the rate of living and the oxidative damage theories of aging. To test this hypothesis, we delivered a highly controlled intervention (STAR Methods), after Y1, the CR group achieved a 16.5% ± 1.5% reduction in energy intake (or CR) from baseline with an overall 14.8% ± 1.5% CR over the entire 2-year intervention (Figure 2A). Despite a slight tendency to gain weight, there was no change in energy intake in the control group from baseline at either time point (Y1, −1.8% ± 2.0% CR; Y2, −1.7% ± 2.0% CR). Subjects in the CR group experienced a significant weight loss at Y1 (−9.4 ± 0.4 kg), which was maintained at Y2 (−8.7 ± 0.4 kg; Figure 2B). Subjects in the control group essentially maintained weight during the 2-year period (Figure 2B). In the CR group, the majority of weight loss (70.7%) was fat mass (Y1, −6.7 ± 0.3 kg; Y2, −5.9 ± 0.3 kg; p < 0.0001 from baseline, within group effect); however, a significant loss in fat-free mass (Y1, −2.9 ± 0.2 kg; Y2, −3.1 ± 0.2 kg; p < 0.0001 from baseline, within group effect) was also observed from baseline at both time points (Figure 2B).

CR for 2 Years Resulted in Metabolic Adaptation Measured in a Metabolic Chamber

Sedentary 24-hr energy expenditure (24hEE) was significantly reduced from baseline in both the CR and control groups at Y1 and Y2 (Table 1), whereas energy expenditure during sleep (SleepEE) was reduced from baseline only in the CR group at both time points (Table 1). In response to the reduced body weight, we observed an approximate 10% drop in absolute SleepEE. After taking the loss of metabolic tissues (fat-free mass and fat mass) into account, SleepEE was still reduced by ~7% in the CR group, indicating a metabolic adaptation in comparison with the control group (Figure 3A; p < 0.02). Similarly, 24hEE adjusted for changes in body composition (fat-free mass and fat mass) was significantly decreased from baseline at Y1 and Y2, but not differently from the control group (Figure 3B; p > 0.55).

An ongoing debate among metabolism, obesity, and aging investigators is whether a chronic deficit in energy intake leads to metabolic slowing or a decreased rate of living. This phenomenon, which has been termed “metabolic adaptation,’’ defines a reduction in EEs that is larger than expected for a reduction in the respiring mass due to a caloric deficit (Heilbronn and Ravussin, 2003). It is thought that the rate of biological aging may be delayed by prolonged CR through a reduction in the rate of living (Sacher and Duffy, 1979), leading ultimately to reduced oxidative damage. Together these theories imply that increased metabolism (above what is required to support the respiring mass)
and the resultant increased production of ROS lead to a shorter lifespan unless these ROS are removed by antioxidant mechanisms.

Support for the rate of living hypothesis as a mechanism, which may extend lifespan in mammals, is debated (Speakman and Mitchell, 2011). Indeed, some of this conflict is due to discrepancies in the different degrees and duration of the imposed CR, the timing of the EE evaluation following the initiation of CR, and whether EE was measured under basal or free-living conditions, which includes physical activity. However, probably the most likely source of conflicting evidence is due to conclusions being drawn from EE measurements without appropriate
a 30% CR diet had no impact on oxygen consumption (measured over 36 hr) after 1 year in comparison with controls (Kemnitz et al., 1993). However, EE (night time and 24 hr) examined in the same cohort after 30 months was significantly lower in CR monkeys (Ramsey et al., 1997). This agrees with a reduction in total daily EE (adjusted for fat-free mass) observed in a different colony undergoing a 26%–31% CR for more 10 years. Yet despite a consistently lower 24hEE in a third colony exposed to a 30% CR, the reduced EE was not different from the control animals (Lane et al., 1995).

In our earlier pilot study, which achieved 19% CR but across only 6 months, we observed a significant metabolic adaptation of EE (24 hr and sleep) measured in a metabolic chamber that was paralleled by a reduced oxidative damage to DNA (Heilbronn et al., 2006). The multi-center CALERIE trial in 218 individuals, using a measure of resting metabolic rate with a bedside indirect calorimeter (ventilated hood), observed a metabolic adaptation after 1 year in comparison with the controls (ad libitum diet), but this adaptation was no longer significant after another year of weight stability (Ravussin et al., 2015).

Believed to be a mechanism for energy conservation, metabolic adaptation has been the focus of weight loss (not specifically CR) in overweight or obese individuals undergoing intensive dietary interventions (Johannsen et al., 2012; Knuth et al., 2014; Rosenbaum et al., 2008). Weight loss-induced metabolic slowing has been reported in overweight/obese individuals with weight loss maintenance persistent for up to 7 years (Rosenbaum et al., 2008). However, the weight loss literature has not focused on quantifying the downstream effects on oxidative damage, which is the other key assumption in a reduced energy flux for delaying biological aging and potentially extending lifespan.

**Physical Activity**

Recent investigations in non-human primates (Yamada et al., 2013) allude to increased physical activity at a lower metabolic cost with sustained CR. The energy cost of physical activity, termed activity-related energy expenditure (AREE) was calculated as the cost of daily activities beyond sleep using linear regression model of total daily energy expenditure and SleepEE at baseline (STAR Methods). We observed no significant treatment effect for activity-related EE (AREE) (p = 0.20). AREE in the CR group was not changed at Y1, but was significantly decreased from baseline at Y2 (−119 ± 55 kcal/day; p = 0.03, within group effect). In the control group, there was no change in AREE from baseline at either time point. The mean change in spontaneous physical activity (SPA) (kcal/day) measured in the metabolic chamber was not different between the CR and control groups (p = 0.46, treatment main effect). SPA was significantly decreased from baseline in the CR group at both Y1 and Y2 (Y1, −29 ± 9 kcal/day; Y2, −30 ± 9 kcal/day; p < 0.01 for both, within group effect), suggesting a reduced energy cost of activity in the chamber.

The lack of effect of CR on physical AREE was echoed in our preliminary 6-month study (Redman et al., 2009). Although the measurement of SPA in the metabolic chamber alludes to a possible reduction in activity with CR, physical activity was unfortunately not objectively measured in the present study while participants were free living.
Table 1. Physical Characteristics of 53 Men and Women during Weight Maintenance at Baseline and Following 1 and 2 Years of CR

<table>
<thead>
<tr>
<th>Table 1. Physical Characteristics of 53 Men and Women during Weight Maintenance at Baseline and Following 1 and 2 Years of CR</th>
<th>Ad Libitum Group (Control, n = 19)</th>
<th>Calorie Restriction Group (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>ΔY1</td>
</tr>
<tr>
<td>Age (years)</td>
<td>39.0 ± 5.4</td>
<td>–</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>71.0 ± 8.3</td>
<td>0.6 ± 0.6</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>25.5 ± 1.6</td>
<td>0.2 ± 0.2</td>
</tr>
<tr>
<td>Body fat (%)</td>
<td>32.9 ± 5.5</td>
<td>0.2 ± 0.4</td>
</tr>
<tr>
<td>Fat mass (kg)</td>
<td>23.4 ± 4.0</td>
<td>0.4 ± 0.4</td>
</tr>
<tr>
<td>Fat-free mass (kg)</td>
<td>48.3 ± 8.1</td>
<td>0.3 ± 0.3</td>
</tr>
<tr>
<td>Energy requirement (kcal/day)</td>
<td>1782 ± 242</td>
<td>–</td>
</tr>
</tbody>
</table>

24hEE (kcal/day) | 1893 ± 250 | –90 ± 28 | –81 ± 28 | 1834 ± 244 | –209 ± 21 | –186 ± 21 |
SleepEE (kcal/day) | 1523 ± 219 | 12 ± 25 | –6 ± 25 | 1530 ± 197 | –170 ± 18 | –160 ± 18 |
T3 (ng/dL) | 121.4 ± 20.1 | –9.1 ± 3.6 | –13.3 ± 3.6 | 115.9 ± 24.4 | –23.5 ± 2.7 | –29.9 ± 2.7 |
T4 (μg/dL) | 7.6 ± 0.9 | 0.01 ± 0.22 | 0.14 ± 0.22 | 7.1 ± 1.5 | –0.29 ± 0.17 | –0.73 ± 0.17 |
TSH (μU/mL) | 1.63 ± 1.25 | –0.04 ± 0.11 | –0.26 ± 0.11 | 1.31 ± 0.63 | –0.15 ± 0.09 | –0.16 ± 0.08 |
Leptin (ng/mL) | 183.6 ± 146.0 | –0.52 ± 1.6 | –0.63 ± 1.6 | 193.9 ± 171.5 | –11.4 ± 1.2 | –9.3 ± 1.2 |
Insulin (μU/mL) | 6.5 | 0.7 ± 0.5 | 0.5 ± 0.5 | 5.1 ± 2.4 | –1.5 ± 0.4 | 0.2 ± 0.4 |
2,3-dinor-iPF(2α)-III (ng/mg Cr) | 2.17 ± 1.03 | –0.09 ± 0.17 | –0.07 ± 0.17 | 2.16 ± 0.87 | –0.42 ± 0.12 | –0.49 ± 0.12 |

Baseline data are presented as means ± SD. Change from baseline data is the adjusted LS mean ± SE from the mixed linear models, which includes the baseline value as a covariate. BMI, body mass index; 24hEE, 24-hr energy expenditure; SleepEE, energy expenditure during sleep (02:00–05:00 hr); T3, triiodothyronine; T4, thyroxine; TSH, thyroid-stimulating hormone.

*Denotes significant within group change from baseline (p < 0.05).

Mediators of Energy Metabolism, Biomarkers of Aging, and Relationship with Metabolic Adaptation

As expected from the differential changes in fat mass between the treatment groups, there was a significant treatment effect for the change in leptin (p < 0.001, treatment main effect), with significant reductions from baseline in the CR group at both Y1 and Y2, and no observed changes in the control group (Figure 4A). Triiodothyronine (T3) concentrations were significantly reduced from baseline in the CR group at Y1 (Y1, –23.5 ± 2.7 ng/dL; Y2, –29.9 ± 2.7 ng/dL; p < 0.0001 for both, within group effect), and that was significantly different from the change in the control group (p < 0.01, treatment main effect). Similarly, there was a significant treatment effect observed for the change in thyroxine (T4) concentrations (Figure 4B; p = 0.02), and the post hoc comparison revealed that the change in T4 concentration from baseline in the CR group was only significant at Y2 (p < 0.0001). This reduced activity of the thyroid axis was not supported by a change in the thyroid-stimulating hormone (TSH) (Y1, –0.15 ± 0.09 μU/mL; Y2, –0.16 ± 0.08 μU/mL; p < 0.10 for both, within group effect) or reverse T3 (data not shown). Sympathetic nervous system activity assessed through excretion of urinary catecholamines over 24 hr during the chamber was not changed from baseline for epinephrine or norepinephrine in either group at Y1 or Y2. Core temperature recorded over 24 hr was not changed during the weight loss phase (Y1, –0.01°C ± 0.03°C; p = 0.88, within group effect); however, with weight maintenance and sustained CR (Y2), there was a trend for core temperature to be decreased from baseline (Y2, –0.06°C ± 0.03°C; p = 0.07, within group effect). When daytime (08:00–22:00 hr) and nighttime (02:00–05:00 hr) temperatures were considered separately, no change in daytime temperature was observed in the CR or control at either time point and therefore the reduced 24-hr core temperature in the CR group at Y2 was attributed to a reduction in core body temperature recorded at night (Y1, –0.05°C ± 0.05°C, p = 0.30; Y2, –0.10°C ± 0.05°C, p = 0.05, within group effect).

While there was no observed treatment group effect on the changes in fasting concentrations of DHEAS, there was a significant interaction (diet intervention group by time) for fasting insulin (p < 0.05), with a significant reduction in insulin concentration in the CR group at Y1, which was no longer evident at Y2 (Y1, –1.5 ± 0.4 μU/mL, p < 0.001; Y2, 0.15 ± 0.4 μU/mL, p = 0.70, within group effect). Furthermore, there was a significant increase in adiponectin concentrations (high molecular weight) from baseline in the CR group (Y1, 1,188 ± 275 ng/mL; Y2, 1,185 ± 271 ng/mL; p < 0.001 for both, within group effect), which was different from control group (Y1, 23 ± 363 ng/mL; Y2, –12 ± 722 ± 363 ng/mL; within group effect) and at both time points (treatment main effect, p < 0.001).

During the weight loss phase (Y1), the metabolic adaption in SleepEE (SleepEE residual) was associated with greater reductions in leptin (Figure 4C; r = 0.35; p = 0.01), but not in the thyroid axis activity (T3, T4, TSH, or reverse T3). At Y2, however, when weight loss was maintained, the relation between metabolic adaptation in SleepEE and leptin was no longer significant (p = 0.22), but the metabolic adaptation was correlated with the reduction in T4 concentrations (Figure 4D; r = 0.33; p = 0.02).

In comparison with the control group, significant reductions in hormonal mediators of energy metabolism including leptin and thyroid hormones (T3 and T4), and an increase in adiponectin, were observed in the CR group. However, the relationship of the changes in these hormones to the metabolic adaption differed in relation to CR during weight loss (Y1) compared with CR during weight loss maintenance (Y2). The CR group also demonstrated attenuation in two well-described...
biomarkers of aging: nighttime core body temperature and fasting insulin.

There appear to be two distinct hormonal mechanisms during CR that potentially influence the development and sustenance of the metabolic effects. During the weight loss phase, we observed a 28% reduction in fat mass and a parallel reduction in leptin. We have previously shown that leptin is a determinant of metabolic adaptation during CR (Lecoultre et al., 2011) and independent of the changes in fat-free mass and fat mass. Indeed, the change in leptin after 1 year of CR was significantly associated with the metabolic adaptation during sleep; however, this relationship was no longer evident after Y2, when weight and fat mass loss were maintained but the metabolic adaptation still present. The mechanisms linking leptin to metabolic adaptation are unclear, even if leptin replacement in obese individuals who had undergone a 10% weight loss rescued in part the metabolic adaptation and reduction in thyroid hormones (Rosenbaum et al., 2002). With prolonged CR and weight loss maintenance, the hormone milieu changes with less contribution from obesity-related hormones (insulin and leptin) and greater contribution from metabolic hormones (T3 and T4). A reduction in thyroid axis activity is a hallmark feature of the hypometabolic state with weight loss, and has been described as a biomarker of aging (Roth et al., 2002b). In the non-human primate colonies (DeLany et al., 1999; Lane et al., 1996; Ramsey et al., 2000; Roth et al., 2002a) exposed to CR diets, and in individuals either naturally exposed to CR or self-practicing CR diets (Fontana et al., 2006; Soare et al., 2011), reduced thyroid hormones and lower core body temperatures are also reported. Whether these biomarkers are necessary drivers for maintaining metabolic adaptation or a consequence is unknown and cannot be discerned from our study.

Markers of Oxidative Stress

Urinary F2-isoprostane excretion (2,3-dinor-iPF(2α)-III) was significantly reduced from baseline at Y1 and Y2 in the CR group (Y1, \(-0.42 ± 0.12\) ng/mg Cr; Y2, \(-0.49 ± 0.12\) ng/mg Cr; \(p < 0.01\) for both, within group effect) and not changed in the control group (\(p > 0.5\) for both time points; data not shown). The pairwise comparison showed that the difference in 2,3-dinor-iPF(2α)-III concentrations was significant between CR and control at Y2 \((p < 0.05)\). Similarly, the three additional isomers of F2-isoprostanes (iPF(2α)-III, iPF(2α)-VI, and 8,12-iso-iPF(2α)-VI) were significantly reduced from baseline in the CR group at Y2 \((p < 0.05)\), within group effect) and not changed in the control group, but no treatment effects were observed. The change in 2,3-dinor-iPF(2α)-III concentrations from baseline to Y2 (expressed as percent change) within the CR group was associated with 24hEE metabolic adaptation \((r = 0.33; p = 0.05)\) and percent CR achieved \((r = -0.36; p = 0.05)\). Serum protein carbonyl concentrations were not changed from baseline at Y1 or Y2 in either the CR or control group. This discordance has also been observed in previous studies (Heilbronn et al., 2006). However, urinary F2-isoprostanes are thought to be
more sensitive biomarkers of oxidative stress in both animals (Kadiiska et al., 2005) and humans (Il'yasova et al., 2010), and are sensitive to changes in age and caloric restriction (Ward et al., 2005), whereas protein carbonyls are less sensitive to oxidative assault (Il'yasova et al., 2009; Kadiiska et al., 2005).

The “free radical theory of aging” or oxidative stress hypothesis is a well-supported theory of aging. It is widely accepted that the metabolic rate of an organism is a major factor in the rate of aging and is inversely related to its lifespan (Sohal and Allen, 1985). In addition, since 1%–3% of consumed oxygen is associated with the production of ROS, namely superoxide, hydrogen peroxide, and the hydroxyl ion (Alexeyev et al., 2004), the production of these highly reactive molecules is thought to be proportional to the metabolic rate of an organism. Numerous studies have shown that modulation of the oxidative stress of an organism through prolonged CR retards the aging process in various species, including some mammals (Sohal and Weindruch, 1996; Weindruch et al., 1986) and possibly humans (Heilbronn et al., 2006).

In support for a CR-induced metabolic slowing and reduction in oxidative stress, the CR group in this investigation had a significant reduction in urinary 2,3-dinor-iPF(2α)-III isoprostane excretion after both 1 and 2 years and three other F2 isomers after 2 years. The reductions in isoprostane excretion were significantly associated with metabolic slowing (metabolic adaptation) in 24hEE at Y2. This finding may emphasize the necessity for long-term studies of sustained CR in humans. Interestingly, reduced levels of oxidative damage have not been reported in centenarians (Klapcińska et al., 2000; Paolisso et al., 1998). Furthermore,
in a large study of nonagenarians residing in Louisiana, we did not find an association between a reduced age-related decline in energy metabolism and oxidative damage to DNA (Frisard et al., 2007). This could bring into question the validity of the oxidative damage theory of aging, particularly as it relates to the rate of living, or alternatively it could point to technical limitations in the measurement of ROS with only indirect biomarkers including urinary protein carboxylation and/or F2-isoprostane excretion rates and/or measurement of EE (bedside calorimeter versus metabolic chamber). These methods may be either insensitive to the small changes to energy efficiency (metabolic adaptation) with CR, or alternatively ROS accumulation may not be attenuated with CR but buffered by the antioxidant defenses of the organism (Schachter et al., 1993). Indeed, observational studies in individuals who live to over 100 years have higher levels of several antioxidant molecules (Mecocci et al., 2000), including those individuals residing on Okinawa (Suzuki et al., 2010), who have been exposed to natural CR across most of their lifespan.

In the exploration of a potential mechanism linking the rate of living and oxidative stress theories to explain the benefit of prolonged CR on aging, it is not surprising that the work has focused on mitochondria. Mitochondrial metabolism is the major endogenous source of ROS production (Fulle et al., 2004). However, the findings from the CR studies do not explain how changes in mitochondrial metabolism lead to lower ROS production. For example, CR in rats has been shown to reduce mitochondrial proton leak and production of hydrogen peroxide (Hagopian et al., 2005), although ROS generation is proportional to transmembrane potential and is downregulated by proton leak (Brookes, 2005; Stowe and Camara, 2009). In monkeys and humans undergoing CR of a shorter duration, CR has been shown to induce robust increases in PGC-1 and mitochondrial biogenesis (Civitarese et al., 2007; McKiernan et al., 2012; Stein et al., 2012). As a result of mitochondrial biogenesis, CR results in improved mitochondrial function or mitochondrial efficiency, decreased total body oxygen consumption, and therefore decreased production of ROS (Civitarese et al., 2007). Indeed, an increase in skeletal muscle work efficiency has been observed in obese individuals with a metabolic adaptation following weight loss (Rosenbaum et al., 2003). Furthermore, in our previous 6-month study (Heilbronn et al., 2006), we observed a reduced energy cost of physical activity after CR.

**Overall Conclusions and Limitations of Study**

In summary, according to the rate of living theory, those individuals who are the most efficient at utilizing energy should experience the greatest longevity. Observational studies of human aging have shown higher mass-adjusted metabolic rate (24hEE or resting EE) is associated with disease burden (Fabbri et al., 2015; Schrack et al., 2014) and is a predictor of early mortality (Jumpertz et al., 2011; Ruggiero et al., 2008). Interventions with the capacity to induce a sustained slowing of energy metabolism such as CR should remain a focus of longevity research because randomized clinical trials and cohort studies are lacking. With careful phenotyping of energy metabolism, biomarkers of aging, and oxidative stress, this modest, 2-year study of human CR identified a reduction in the rate of living along with a reduction in systemic oxidative stress. The duration of imposed CR being for only 2 years clearly limits any extrapolation or speculation of the impact of CR on longevity in humans. Notably, many biomarkers of aging (that could be a consequence of the overall improved metabolic profile commensurate with adipose tissue loss) were also improved in these young, healthy individuals. There is a clear need for continued investigations of CR in humans, since the non-human primate data are not entirely conclusive on the extension in the average and maximal lifespan but provide strong evidence for extensive health benefits including improved quality of life. The CALERIE study did not prescribe a particular diet composition and thereby this research cannot be extrapolated to infer diet recommendations to promote healthier aging apart from a reduction in calories. Future research on CR for healthy aging would benefit from considering the diet quality of individuals who have successfully defied the aging process (e.g., antioxidant content). Finally, future studies of CR may benefit from a combined approach with use of a CR mimetic such as resveratrol or greater attention to the dietary prescription, which would include foods that will increase antioxidant defense systems.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Study Design
  - Participants
- **METHOD DETAILS**
  - Study Interventions
  - Energy Intake and Calorie Restriction
  - Total Daily Energy Expenditure
  - Anthropometrics and Body Composition
  - Sedentary 24-hour Energy Expenditure
  - Core Body Temperature
  - Physical Activity
  - Oxidative Stress
  - Clinical Chemistry
- **QUANTIFICATION AND STATISTICAL ANALYSIS**
  - Sample Size Estimation
  - Statistical Analysis

**ACKNOWLEDGMENTS**

This work was funded by the NIH (R01 AG029914 and U01 AG020478 to E.R.), and supported in part by P30DK072476 (Pennington/Louisiana NOPR) and U54 GM104940 (Louisiana Clinical and Translational Science Center). We are indebted to the commitment of the study participants who invested over 2 years of their life to participate in this clinical trial. The efforts of the CALERIE data coordinating center (James Rochon, William Krauss, and Manjushri Bhapkah) are also acknowledged and greatly appreciated. We thank Dr. Donald Ingram for his critical review and thoughtful insights, which helped to shape this paper. The CALERIE phase 2 trial (NCT00427193) and this ancillary study (NCT02695511) are registered as clinical trials at http://clinicaltrials.gov/.

**AUTHOR CONTRIBUTIONS**

E.R. and L.M.R. designed the study, obtained funding, conducted the research, interpreted the results, and wrote the manuscript. D.I. conducted...
the research. S.R.S. and C.K.M. designed the study, obtained funding, and conducted the research. J.H.B. performed the statistical analysis. All authors reviewed and approved the final draft of the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: June 12, 2017
Revised: December 23, 2017
Accepted: February 20, 2018
Published: March 22, 2018

REFERENCES


Pearl, R. (1928). The Rate of Living (University Press).


CONTACT FOR REAGENT AND RESOURCE SHARING

The dataset pertaining to the current study is available upon written request. Resources will be shared in accordance with appropriate data use agreements and IRB approvals for secondary analyses. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Leanne Redman (leanne.redman@pbrc.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Study Design
CALERIE 2 (Rochon et al., 2011) was a two year multi-center, parallel-group, randomized controlled trial that recruited healthy individuals to receive an intervention aimed at reducing energy intake by 25% (CR group) or to maintain habitual energy intake on an ad libitum basis (control group). Two hundred and twenty individuals from Pennington Biomedical Research Center (Baton Rouge, LA), Washington University (St. Louis, MO) and Tufts University (Boston, MA) were randomized in this multi-center study (NCT00427193) for which Duke University, (Durham, NC) was the coordinating center (Rochon et al., 2011). The present ancillary study (NCT02695511) was approved by the IRB of the Pennington Biomedical Research Center and offered only to the 80 individuals enrolled in the parent study at this site. Interested individuals provided written informed consent for the additional visits and procedures. Following baseline assessments, participants were randomized to adhere for two years to a diet that targeted 25% calorie restriction (CR group) or calorie intake ad libitum (AL; Control group) according to a 2:1 allocation in favor of the CR group. Randomization was stratified by study site, sex and BMI dichotomized into normal weight (22.0 kg/m² < BMI < 25.0 kg/m²) and overweight (25.0 kg/m² < BMI < 28.0 kg/m²). Ancillary testing included an additional outpatient visit and a 24-hour stay in a metabolic chamber at baseline, and after 1 year (Y1; 12 months) and 2 years (Y2; 24 months) of intervention. The Clinic staff involved in the collection of study outcomes was blinded to the treatment group assignments.

Participants
Men and women were aged 20 to 50 years and 20 and 47 years, respectively, and had body mass index (BMI) between 22.0 to 27.9 kg/m² at the initial screening visit. Potential participants in the ancillary study were excluded for claustrophobia, contraindications to MRI and history of blood clotting disorders. The CONSORT diagram summarizing throughput of participants in the study is provided in Figure 1 and the characteristics of the participants at baseline is summarized in Table 1.

METHOD DETAILS

Study Interventions
From day 1, the CR intervention targeted a sustained 25% restriction of energy intake prescribed on the basis of the energy requirements determined from two, 14-day doubly labeled water measures at baseline (Redman et al., 2014; Rickman et al., 2011). The goal
for the intervention was adherence to a mathematically predicted weight loss trajectory that reached 15.5% below baseline weight after one year of intervention followed by maintenance of this weight over the second year (Pieper et al., 2011). Participants received a weekly weight loss graph that showed a targeted weight range which was used as the primary tool to maintain adherence during the intervention. Because of the variability in projected weight loss needed to achieve 25% CR, participants were also provided with guidance indicating a “zone of acceptable weight loss” which ranged from 12 to 22%. Nutritional and behavioral guidance was customized and modified to decrease the degree to which weight change differed from the target. Adherence to 25% CR was further fostered by provision of meals for the first 27 days of the study. Participants were fed their assigned caloric prescription in the form of three, 9–day diets. The food provision was used to educate on portion size, energy content and anticipated diet changes necessary to maintain 25% CR with different types of dietary patterns. The behavioral intervention included delivery of a structured curriculum in regular group and individual meetings with interventionists (clinical psychologists and nutritionists) from a standardized treatment manual developed specifically for the study (Rickman et al., 2011). Participants randomized to the control group were advised to continue their current diets on a completely ad libitum basis. No specific level of physical activity was required or recommended for either group. All participants received a multivitamin (Nature Made Multi Complete, Pharmavite LLC, Mission Hills, CA) and calcium supplement (1000mg/d, Douglas laboratories, Pittsburgh, PA) to foster nutritional adequacy of the self-selected diets.

### Energy Intake and Calorie Restriction

Energy intake was calculated at baseline by total daily energy expenditure (doubly labeled water) and during the trial between baseline and Y1 as well as baseline and Y2 by the intake/balance method derived from total daily energy expenditure (doubly labeled water) and the changes in energy content of fat mass (9,300 kcal/kg) and fat-free mass (1,100 kcal/kg) from DXA (Racette et al., 2012). The percent reduction in energy intake (%CR) achieved during each interval was defined as; %CR = 100 x (Energy intake at baseline – EI during Interval) / Energy intake at baseline.

### Total Daily Energy Expenditure

For each doubly labeled water (DLW) assessment, two baseline urine samples were collected before subjects consumed an oral cocktail (1.5 g/kg body weight) containing 0.086 g of $^2$H$_2$O (99.98 %$^2$H) and 0.138 g H$_2^{18}$O (100%$^{18}$O) per kg body weight (Redman et al., 2009). After dosing, participants were asked to void their bladder at approximately 1–3 h after ingestion (this sample was discarded) and to collect six additional, timed urine samples: two approximately 4.5h and 6h after dosing, two on day 7, and two on day 14. Measurement of hydrogen and oxygen isotope enrichments were measured by gas–isotope–ratio mass spectrometry at the USDA/ARS Children’s Nutrition Research Center Stable Isotope Laboratory (Houston, TX) (Racette et al., 1994; Wong et al., 1992). Carbon dioxide production rate (VCO$_2$) was calculated from the fractional turnover rates of $^2$H ($k_H$) and $^{18}$O ($k_O$) (Racette et al., 1994) and converted to TDEE based on an energy equivalent of a liter of CO2 to be 3.815/RQ + 1.2321 where the RQ was determined for each individual using food diaries and changes in body composition.

### Anthropometrics and Body Composition

Metabolic body weight was measured (Scale Tronix 5200, White Plains, NY) in the morning after an overnight fast and voiding while wearing a surgical gown which was subtracted from the total weight. Body composition (fat, lean, and bone) was measured by dual X–ray absorptiometry (DXA; Hologic QDR 4500A; Hologic, Bedford, MA) according to a standardized protocol and all scans were analyzed at a centralized reading center (University of CA, San Francisco) using Hologic software version Apex 3.3.

### Sedentary 24–hour Energy Expenditure

Participants entered a metabolic chamber at approximately 0800h after an overnight fast for measurement of 24 hour sedentary energy expenditure (24hEE) and sleeping energy expenditure (SleepEE). Meals were prepared by the metabolic kitchen and served according to a fixed schedule. At baseline, the energy intake provided was estimated according to an equation and adjusted during the day on the basis of actual measured energy expenditure of the first 7 hours of measurement (Nguyen et al., 2003). For the subsequent chambers, the energy content of the food was held constant for control participants and was 75% of measured baseline 24–hour energy expenditure for CR participants. SleepEE was assessed between 0200–0500h for those minutes that activity is less than 1%. During their stay in the chamber, no exercise was allowed. The change in 24hEE and SleepEE is expressed as the residual EE which is the difference between the measured value and the value predicted for the EE measurement (on the basis of weight and body composition) at each time point. The predicted values were derived from a linear regression at baseline for the 71 participants using fat–free mass, fat mass, age and sex as covariates;

1. $24hEE$ (kcal/d) = 1100 + 17.2 (fat–free mass, kg) + 4.6 (fat mass, kg) – 1.9 (age, y) – 167 (sex; 1=female, 0=male); $R^2=0.70$, $p<.0001$.  
2. $SleepEE$ (kcal/d) = 749 + 17.6 (fat–free mass, kg) + 3.2 (fat mass, kg) – 2.6 (age, y) – 58 (sex; 1=female, 0=male); $R^2=0.70$, $p<.0001$.  

Please cite this article in press as: Redman et al., Metabolic Slowing and Reduced Oxidative Damage with Sustained Caloric Restriction Support the Rate of Living and Oxidative Damage Theories of Aging, Cell Metabolism (2018), https://doi.org/10.1016/j.cmet.2018.02.019
The difference in the residual EE (follow–up minus baseline) was then used as a marker of the extent to which energy expenditure adapted to calorie restriction independently from the changes in body mass and body composition with negative values indicating metabolic adaptation (Galgani and Santos, 2016).

Core Body Temperature
Core body temperature (VitalSense, Mini–Mitter, Bend, OR) was measured and recorded every minute during the energy expenditure measurement in the metabolic chamber. Mean temperature over 24 hours as well as mean day time (0800–2230h) and night time (0200–0500h) temperatures were calculated.

Physical Activity
The energy cost of physical activity, termed activity related energy expenditure (AREE) was calculated as the cost of daily activities beyond sleep using linear regression model of total daily energy expenditure by doubly labeled water measures (TDEE) and SleepEE at baseline: TDEE (kcal/d) = 859 + 1.1 (SleepEE, kcal/d) + 4.1 (age, y) – 340 (sex; 1=female, 0=male); R²=0.66, p<.0001. AREE is positive for subjects with higher physical activity compared to average and negative for subjects with lower physical activity than average (Redman et al., 2009). Second, the calories expended in spontaneous physical activity (SPA) were determined by microwave motion detectors and indirect calorimetry in the metabolic chamber.

Oxidative Stress
Our primary measure of oxidative damage, urinary 2,3-dinor–IPF(2α)–III was measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS) on a Shimadzu 20A series LC and Applied Biosystems API 4000 QTrap MS/MS instruments as previously described (Il'yasova et al., 2010). We also measured three additional isomers of F2–isoprostanes; IPF(2α)–III, IPF(2α)–II, and VI, and 8,12–iso–IPF(2α)–VI as exploratory variables. Urine specimens were diluted to 0.65 mg/mL creatinine, and samples with creatinine levels equal to or below this value were analyzed without dilution. Sample preparation included addition of internal standards [IPF(2α)–III–d4, 8,12–iso–IPF(2α)–VI–d11, IPF(2α)–VI–d4] and 10 μL 1M HCl; washing of samples (500 μL) with 1 mL hexane; extraction of the analytes by ethyl acetate/hexane mixture (3/1, v/v); evaporation of the liquid and resuspension of the residue in 150 μL of a mixture containing 70% mobile phase A (0.1% formic acid in water) and 30% methanol. Using LC–MS/MS, 100 μL of sample were injected into two solid core C18 columns (Phenomenex Kinetex C18, 150 x 4.6 mm) in series to achieve chromatographic separation of the F2–isoprostane isomers. The mass spectrometer was operated in negative mode with the following MRM transitions (m/z): 353/193 [IPF(2α)–III], 357/197 [IPF(2α)–III–d4], 325/237 [2,3–dininor–IPF(2α)–III], 353/115 [IPF(2α)–VI and 8,12–iso–IPF(2α)–VI], 364/115 [IPF(2α)–VI–d11], and 357/115 [8,12–iso–IPF(2α)–VI–d4]. Calibration samples covering the expected range of concentrations were prepared by adding pure material into pooled human urine, injected before and after the patient samples. Lower limits of quantification (LLOQ, >80 % accuracy) were 0.007, 0.34, 0.25, and 0.12 mg/mL for iPF(2α)–III and 2,3–dinor–IPF(2α)–III, IPF(2α)–VI, and 8,12–iso–IPF(2α)–VI, respectively. As a complimentary measure of oxidative damage, serum protein carbonyls were determined using a modified 2,4–dinitrophenylhydrazine assay (Matés et al., 2000).

Clinical Chemistry
Fasting blood samples were collected and the following assays were performed at the CALERIE central biochemistry laboratory at Vermont University or at the Clinical Chemistry Core at Pennington Biomedical Research Center: thyroid stimulating hormone (TSH) and triiodothyronine (T3) by chemiluminescent immunoassay (ADVIA Centaur, Bayer Health Care, Deerfield, IL); thyroxine (T4) by particle–enhanced immunonephelometric assay, (BN II, Siemens, Deerfield, IL); reverse T3 by multiplex immunoassay (Bio–Plex, Bio–Rad Laboratories, Hercules, CA); leptin by multiplex immunoassay (Bio–Plex, Bio–Rad Laboratories, Hercules, CA); and insulin by chemiluminescent immunoassay (Elecsys 2010, Roche Diagnostics, Indianapolis, IN). Nitrogen, creatinine, norepinephrine and epinephrine were measured in a 24 hour pooled urine sample collected during the chamber stay.

QUANTIFICATION AND STATISTICAL ANALYSIS

Sample Size Estimation
This study was powered on the ability to detect a significant adaptation in energy metabolism (24hEE, SleepEE) from baseline and to detect differences in this adaptation between the two diet groups (AL vs CR). Sample size estimates were derived from the data obtained in our 6 month pilot study where the standard deviation in EE was assumed to be 140 kcal/d. Anticipating that a maximum of 75 subjects (50 in CR and 25 in control) would enroll in the ancillary study, the minimal detectable metabolic adaptation within groups is 60 kcal/d and between groups is 100 kcal/d to achieve a power ≥ 80%.

Statistical Analysis
All analyses were carried out using SAS/STAT software, Version 9.4 of the SAS System for Windows (SAS Institute, Cary, NC, USA) and tests were evaluated using significance level of α=0.05. The per–protocol analysis (see “study subjects and throughput in the Results Section) comprised of computing the change from baseline to Y1 and Y2 in all outcomes which were investigated for fixed effects (treatment group, time) and a treatment–by–time interaction using linear mixed models for repeated measures. The models included the baseline outcome value as a covariate. A random subject effect was also included to account for intra–individual
correlations over time. Two-sample t-tests derived from least squares means (LSM) were used to compare adjusted mean changes between treatment groups (AL vs CR) and to test for group differences in adjusted mean change at Y1 and Y2. This same method was used to model and assess differences in percent change from baseline. Finally, Pearson’s correlation analysis was used to assess relationships between %CR and metabolic adaptation, change from baseline in clinical chemistries and for Spearman’s correlation analysis was used to examine relationships between %CR, metabolic adaptation and isoprostane concentrations which were non-normally distributed.